<table><tr><td colspan="1" rowspan="1">Submitter:</td><td colspan="1" rowspan="1">Apex Biotechnology Corp.No. 7, Li-Hsin Road V, Hsinchu Science ParkHsinchu, 30078CHINA (TAIWAN)</td></tr><tr><td colspan="1" rowspan="1">Contact Person:</td><td colspan="1" rowspan="1">Lisa LiuAssistant Manager of Quality Assurance DepartmentApex Biotechnology Corp.No. 7, Li-Hsin Road V, Hsinchu Science ParkHsinchu, 30078CHINA (TAIWAN)email: lisaliu@apexbio.comPhone: 011-886-3-5641952FAX: 011-886-3-5678302</td></tr><tr><td colspan="1" rowspan="1">Date Prepared:</td><td colspan="1" rowspan="1">March 1, 2012</td></tr><tr><td colspan="1" rowspan="1">Trade Names:</td><td colspan="1" rowspan="1">AutoSure Voice 3 Plus Blood Glucose Monitoring SystemAutoSure Plus Blood Glucose Test Strips</td></tr><tr><td colspan="1" rowspan="1">Classification:</td><td colspan="1" rowspan="1">Glucose test system, 21 CFR 862.1345, Class II</td></tr><tr><td colspan="1" rowspan="1">Product Codes:</td><td colspan="1" rowspan="1">CGA, NBW</td></tr><tr><td colspan="1" rowspan="1">Predicate Device:</td><td colspan="1" rowspan="1">AutoSure Voice II Plus Blood Glucose Monitoring System (k1 13098)AutoSure Plus Blood Glucose Test Strip (k1 13098 )</td></tr><tr><td colspan="1" rowspan="1">Device Description:</td><td colspan="1" rowspan="1">The AutoSure Voice 3 Plus blood glucose meter and AutoSure Plus teststrips are used for testing of blood glucose by self-testers at home.Contrex Plus III Glucose Control Solutions are used for quality controltesting of the system.</td></tr><tr><td colspan="1" rowspan="1">Intended Use:</td><td colspan="1" rowspan="1">The AutoSure Voice 3 Plus Blood Glucose Monitoring System is intendedfor the quantitative measurement of glucose in fresh capillary whole bloodsamples drawn from the fingertips, forearm, or palm. The meter includesvoice functionality to assist visually impaired users. It is indicated for layuse by people with diabetes as an aid to monitoring levels in DiabetesMellitus and should only be used by a single patient and it should not beshared. It is not indicated for the diagnosis or screening of diabetes or forneonatal use.The AutoSure Plus Blood Glucose Test Strips are to be used with theAutoSure Voice 3 Plus Blood Glucose Meter to quantitatively measureglucose in capillary whole blood taken from fingertips, palm, or forearm.They are not indicated for the diagnosis or screening of diabetes or forneonatal use.</td></tr><tr><td colspan="1" rowspan="1">Comparison ofTechnologicalCharacteristics:</td><td colspan="1" rowspan="1">The AutoSure Voice 3 Plus system has been modified relative to thepredicate by relocating the 3 operating buttons from the front to the side ofthe meter. The AutoSure Voice 3 Plus meter uses the same test algorithm andtest strips as the predicate meter. Both systems use Contrex Plus IIl controlsolutions.</td></tr><tr><td colspan="1" rowspan="1">Non-ClinicalTesting:</td><td colspan="1" rowspan="1">EMC &amp; Electrical Safety and linearity testing. Results demonstratesubstantial equivalence to the predicate system.</td></tr><tr><td colspan="1" rowspan="1">Clinical Testing</td><td colspan="1" rowspan="1">A user survey shows substantial equivalence in ease-of-use after therelocation of the operation buttons.</td></tr><tr><td colspan="1" rowspan="1">Conclusion:</td><td colspan="1" rowspan="1">Testing demonstrated that the AutoSure Voice 3 Plus system performs in asubstantially equivalent manner to that of the predicate. We conclude thatthe new system is substantially equivalent to the predicate device.</td></tr></table>

Apex Biotechnology Corporation c/o Lisa Liu No. 7, Li-Hsin Road V, Hsinchu Science Park Hsinchu, China (Taiwan) 30078

Re: k120649 Trade Name: AutoSure 3 Plus Blood Glucose Monitoring System Regulation Number: 21 CFR §862.1345 Regulation Name: Glucose test system Regulatory Class: Class II Product Codes: NBW, CGA Dated: June 7, 2012 Received: June 8, 2012

Dear Ms. Liu:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling. and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class I11 (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760: For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/Medical   
Devices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance...

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm

Sincerely yours,

![](images/15fc10e589cc4d24ddcb0fef20224561fc44d9ff4bbea1c3046b8ef2683968dc.jpg)

Coupney H. Lias, Ph.D.   
Dir€ctor   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# 5 Indications for Use Statement

510(k) Number (if known):

Device Name: AutoSure Voice 3 Plus Blood Glucose Monitoring System

Indications for Use:

The AutoSure Voice 3 Plus Blood Glucose Monitoring System is intended for the quantitative measurement of glucose in fresh capillary whole blood samples drawn from the fingertips, forearim, or palm. The meter includes voice functionality to assist visually impaired users. It is indicated for lay use by people with diabetes as an aid to monitoring levels in Diabetes Mellitus and should only be used by a single patient and it should not be shared. It is not indicated for the diagnosis or screening of diabetes or for neonatal use.

The AutoSure Plus Blood Glucose Test Strips are to be used with the AutoSure Voice 3 Plus Blood Glucose Meter to quantitatively measure glucose in capillary whole blood taken from fingertips, palm, or forearm. They are not indicated for the diagnosis or screening of diabetes or for neonatal use.

![](images/e9af7a4ca120b4c6944c7b1e5079b1b86609c29470df6cf65e7384f950f1d9c2.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

510(k) K12 0649